Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Follicular 2Head and Neck Neoplasms 2Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1

Interventions

Rituximab 131Cyclophosphamide 74fludarabine phosphate 51Whole-Body Irradiation 38Peripheral Blood Stem Cell Transplantation 36Mycophenolic Acid 36Tacrolimus 32Etoposide 28Busulfan 28Melphalan 24Lenalidomide 23Prednisone 22Filgrastim 22Cyclosporine 22Bortezomib 22Antilymphocyte Serum 21Vincristine 19Methotrexate 19obinutuzumab 17Bendamustine Hydrochloride 16fludarabine 15Doxorubicin 15Radiotherapy 14ibrutinib 13Dexamethasone 13Cytarabine 13Cord Blood Stem Cell Transplantation 13Carmustine 13pembrolizumab 12idelalisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, Follicular × duvelisib × Clear all
NCT02204982 2023-09-28

DYNAMO + R

SecuraBio

Phase 3 Terminated
13 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02391545 2023-09-28

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

SecuraBio

Phase 1/2 Terminated
55 enrolled 13 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡